NCT00000798View on ClinicalTrials.gov

A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

BIOLOGICAL

HIV-1 Peptide Vaccine, Microparticulate Monovalent

Trial Locations (2)

14642

Univ of Rochester Med Ctr, Rochester

21205

Johns Hopkins Univ / Ctr for Immunological Research, Baltimore

All Listed Sponsors

collaborator

United Biomedical

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000798 - A Phase I Safety and Immunogenicity Trial of UBI Microparticulate Monovalent HIV-1 MN Peptide Immunogen in HIV-1 Seronegative Human Subjects | Biotech Hunter | Biotech Hunter